Drug-induced platelet destruction.
D001666:Binding Sites, Antibody; D001792:Blood Platelets / Q000473:pathology*; D002454:Cell Differentiation / Q000187:drug effects; D002464:Cell Migration Inhibition; D003018:Clot Retraction; D003168:Complement Fixation Tests; D006046:Gold / Q000009:adverse effects; D006493:Heparin / Q000009:adverse effects; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D007428:Intradermal Tests; D010974:Platelet Aggregation; D010977:Platelet Factor 3; D011241:Prednisone / Q000627:therapeutic use; D011802:Quinidine / Q000008:administration & dosage / Q000276:immunology; D012310:Ristocetin / Q000009:adverse effects; D012701:Serotonin / Q000378:metabolism; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis / Q000276:immunology; D013923:Thromboembolism / Q000150:complications; D014508:Urea / Q000009:adverse effects / Q000031:analogs & derivatives; D014635:Valproic Acid / Q000009:adverse effects
D007074:Immunoglobulin G; D012310:Ristocetin; D012701:Serotonin; D010977:Platelet Factor 3; D014635:Valproic Acid; D006046:Gold; D014508:Urea; D006493:Heparin; D011802:Quinidine; C005700:apronalide; D011241:Prednisone